The FDA press release that front-ran a 23.5% biotech run
On August 6, 2026, the FDA granted accelerated approval to Replimune's Tudriqev, a new engineered viral immunotherapy for advanced melanoma, and posted the news to its public press feed. At 20:28 UTC, 28 minutes after the market close, knowfir.st had read the release and mailed subscribers the take, naming Replimune (REPL) the direct beneficiary. From that evening's $12.86 close, the stock climbed to $15.88 by August 26, up 23.5% in 14 trading sessions.
An accelerated approval is about as legible as a market catalyst gets: a federal agency publishes it at a known address, and it names its beneficiary in the first sentence. The catalyst was public at the close, and the repricing still took two weeks to top out.
The receipt
The alert left our system at 20:28:51 UTC, which is 4:28 p.m. in New York on a Thursday whose session closed at 4:00. Here is the delivered take, verbatim:
"The FDA granted accelerated approval to Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for adult patients with unresectable advanced cutaneous melanoma that progressed on prior anti-PD-1 therapy, based on a 24% objective response rate and 14.1-month median duration of response in a 140-patient trial."
"Replimune (REPL) is the direct beneficiary; accelerated approvals for first-in-class oncology agents have historically produced significant single-day moves for small-cap biotechs."
The alert landed after the close, so every number here is measured from the $12.86 close already on the tape. The approval-day pop itself, 8.7% on the August 6 session, is excluded.
The crash, the vote, the approval
The two weeks before the approval were violent. On July 28, staff briefing documents for the FDA's advisory committee concluded that "The overall survival analysis from the single-arm IGNYTE study is not interpretable," and BioSpace reported the stock down more than 32% by late morning. It closed at $5.35, off 38% in a single session. Two days later the Cellular, Tissue, and Gene Therapies Advisory Committee met and, per Fierce Pharma, voted 10 to 3 in the drug's favor. REPL doubled on the outcome, closing July 31 at $11.20, up 107%. It was the program's third attempt, after what Fierce Pharma called "two high-profile FDA rejections." Six days later, the approval landed.
What the tape did after the alert
It did nothing heroic at first: REPL faded 6% on August 7 to $12.06 as sellers took the approval pop. Then it ground higher for two weeks, to $15.88 by the August 26 close, up 23.5% in 14 sessions. The sector tide does part of that work and no more: from the same August 6 close through August 28, XBI, the biotech sector ETF, rose 5% while REPL held a 21% gain, roughly four times its sector.
A reader who, hypothetically, bought the next session's $12.06 close would have been up 31.7% at the August 26 peak; that arithmetic is best-case hindsight on one selected example, and it is not investment advice.
The ripple was in the memo too
The take's ripple section made a second call:
"Broader oncolytic virus platform interest could lift sentiment across gene therapy names."
It also named a rival:
"Competitors developing rival oncolytic or tumor-infiltrating lymphocyte therapies for the same refractory melanoma population — including Iovance Biotherapeutics (IOVA) — face increased competitive pressure."
The sentiment half landed hard. IOVA jumped 43% on approval day, from $4.34 to $6.21, and by August 28 sat 85% above its pre-approval close, against REPL's own 31% from the same base date.
The competitive-pressure half pointed the wrong way over this window: the market read the approval as validation for the whole oncolytic class. The honest ledger, then: cohort call right, direction on the named rival wrong. BMY, whose nivolumab is the combination partner, added 5.3% from the approval close through August 26, about as modest as the take suggested.
Reality check
The strongest case against the front-running frame sits two sections up. The July 30 panel vote was public government process, REPL had already doubled on it, and anyone could have owned the stock at $11.20 a week before the approval. The alert said as much in its own horizon section:
"Short-term, REPL may see a sharp after-hours move on approval surprise value, though the advisory committee met July 30, reducing some element of surprise."
Beta takes another slice: XBI rose 9% over the same August 6 to August 26 window, so part of REPL's 23.5% is simply the sector rising. Front-running here is a claim about timing, and the panel plus the sector tide are the alternative explanations worth weighing. Neither explains the spread REPL opened over its own sector after approval, and neither explains IOVA.
The science also stays conditional. The alert's caveat line asked readers to "note the modest trial size (91 evaluable patients) and single-arm design limit certainty around the efficacy signal," and its ripple section was blunter still: "Accelerated approval carries a confirmatory-trial condition, so REPL faces ongoing regulatory execution risk."
On the commercial side, Fierce Pharma reports Leerink's un-risk-adjusted peak sales estimate at $618 million across roughly 10,000 advanced U.S. melanoma patients a year, numbers that could support this run or undercut it depending on execution.
The window, stated plainly
The measurement window runs from the August 6 close ($12.86) to the August 26 close ($15.88), because the alert landed 28 minutes after the first print and the run's high sits on the second. Ending at a peak flatters any number, so here is what came after: $15.60 on August 27 and $15.50 on August 28, the last close before this post, still up about 21% from approval day. One alert, one name, one selected window; none of it is advice, and the next one will look different.
Accelerated approvals keep coming, and each one posts to the same public feed. It is the pattern we documented when the Pentagon signal front-ran Microsoft's earnings week: a public document, a fast read, a market that takes days to finish the arithmetic. The next Tudriqev will sit on a government server minutes after some close, waiting for whoever reads it first. What will be in your inbox when it is?
Get the next one while it is still a press release. knowfir.st watches more than 30 primary sources, the FDA's press feed among them, and emails subscribers the ones that matter with a short read on why, minutes after they post. The homepage shows real delivered alerts and the live median delivery time, and your first feed is free.